title: [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].
abstract: OBJECTIVE
  To evaluate metformin efficacy and safety in patients with gout and insulin resistance (IR).
  
  
  METHODS
  The trial included 26 patients with gout (criteria of the American collage of rheumatologists) and IR (index HOMA). The inclusion criteria were the following: absence of antigout therapy, normal hepatic and renal function, rejection of alcohol. The drug dose was 1500 mg/day. The study was made of anthropometric and clinical characteristics, 24-h blood pressure monitoring, blood tests for uric acid, glucose, insulin, urea, creatinin, alaninaminotransferase, aspartataminotransferase, lipid spectrum at the first and further visits.
  
  
  RESULTS
  A 6-month metformin therapy significantly changed the levels of glucose, insulin, HDLP and LDLP cholesterol, uric acid, HOMA index. Normouricemia was achieved in 11 patients, a significant lowering of uric acid--in 12 patients. The number of affected joints in 23 patients reduced from 4 (1-5) to 1 (0-2), p < 0.01. Seven patients with achieved normouricemia had no arthritis attacks. In 3 of 10 patients with chronic arthritis joint inflammation persisted. Six patients had dyspepsia during the first week of therapy, 1 patient discontinued the drug because of persistent diarrhea.
  
  
  CONCLUSIONS
  Metformin therapy is safe. It reduces IR. The principal result of the study was lowering of uric acid and attenuation of the articular syndrome.
authors.forename: V G
authors.initials: VG
authors.lastname: Barskova
authors.forename: M S
authors.initials: MS
authors.lastname: Eliseev
authors.forename: E L
authors.initials: EL
authors.lastname: Nasonov
authors.forename: A V
authors.initials: AV
authors.lastname: Volkov
authors.forename: T N
authors.initials: TN
authors.lastname: Tsapina
authors.forename: A V
authors.initials: AV
authors.lastname: Zilov
authors.forename: I A
authors.initials: IA
authors.lastname: Iakunina
authors.forename: E V
authors.initials: EV
authors.lastname: Il'inykh
authors.forename: F M
authors.initials: FM
authors.lastname: Kudaeva
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006073:Gout / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D014527:Uric Acid; D008687:Metformin